Compare JOBY & CORT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JOBY | CORT |
|---|---|---|
| Founded | 2009 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Aerospace | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.8B | 9.7B |
| IPO Year | 2020 | 2001 |
| Metric | JOBY | CORT |
|---|---|---|
| Price | $7.19 | $117.90 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 7 | 5 |
| Target Price | $13.43 | ★ $96.50 |
| AVG Volume (30 Days) | ★ 28.2M | 1.1M |
| Earning Date | 05-05-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.09 |
| Revenue | $53,425,000.00 | ★ $761,407,000.00 |
| Revenue This Year | $114.04 | $26.08 |
| Revenue Next Year | $96.87 | $26.98 |
| P/E Ratio | ★ N/A | $1,331.11 |
| Revenue Growth | ★ 39183.09 | 12.79 |
| 52 Week Low | $6.63 | $28.66 |
| 52 Week High | $19.98 | $126.38 |
| Indicator | JOBY | CORT |
|---|---|---|
| Relative Strength Index (RSI) | 40.27 | 61.38 |
| Support Level | $6.76 | $76.41 |
| Resistance Level | $8.18 | $122.21 |
| Average True Range (ATR) | 0.37 | 3.79 |
| MACD | -0.07 | -0.46 |
| Stochastic Oscillator | 5.01 | 50.31 |
Joby Aviation Inc is a transportation company developing an all-electric, vertical take-off and landing (eVTOL) air taxi for commercial passenger service. Its Joby eVTOL aircraft is designed to transport a pilot and up to four passengers or an expected payload of up to 1,000 pounds at speeds of up to 200 mph. The aircraft is optimized for urban routes, with a target range of up to 100 miles on a single charge. The company is also developing an app-based platform that will help consumers to book rides directly through its service. It has one operating and reportable segment, air transportation and related services. The company's revenue consists of passenger revenue, which includes revenue generated from the transportation of passengers via helicopter or fixed wing aircraft.
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic, and neuropsychiatric disorders by modulating the effect of the cortisol hormone. The company markets Korlym (mifepristone) tablets and its authorized generic version, which is an oral medication for the treatment of hypercortisolism (also known as Cushing's syndrome). Additionally, its pipeline contains several key compounds, such as Relacorilant, Dazucorilant, Miricorilant, etc., that are being evaluated in clinical trials as potential treatments for a variety of serious disorders like hypercortisolism, solid tumors (including ovarian, endometrial, cervical, pancreatic, and prostate cancers), ALS, and MASH.